BioNTech’s Radical Overhaul: 1,860 Job Cuts, Factory Shutdowns, and a €532 Million Loss as Cancer Bet Takes Center Stage

The era of pandemic-era blockbuster revenues at BioNTech has come to a definitive end. The Mainz-based biotech is shuttering four production sites – including its flagship plants in Marburg, Idar-Oberstein, and Tübingen, along with its Singapore facility – and shedding roughly 1,860 of its 8,400 employees by 2027. The complete halt of COVID-19 vaccine manufacturing by 2026 marks the most aggressive restructuring since the company shot to global prominence.

The financial toll of that transition was laid bare in the first quarter. Revenue slumped to €118.1 million from €183 million a year earlier, as demand for mRNA jabs continues to evaporate. BioNTech booked a net loss of nearly €532 million, translating to an adjusted loss of $2.26 per American depositary share – a figure that nonetheless came in slightly better than analyst forecasts.

Management is not standing idle. The board reaffirmed its full-year revenue target of roughly €2 billion and announced a $1 billion share buyback program. That signal of confidence is backed by a formidable war chest: nearly €17 billion in cash and equivalents, a cushion that allows the company to fund its pivot without immediate financing worries.

Wall Street is split on whether the bet will pay off. Goldman Sachs and Wells Fargo retain buy ratings, but Canaccord slashed its price target to $158 after the quarterly numbers. Leerink Partners is even more bearish, having cut its target to $94 in April, citing doubts about the phase 3 trial for the cancer candidate Gotistobart. Meanwhile, research and development spending surged to €557 million last quarter, much of it directed toward the oncology pipeline and the integration of CureVac assets acquired last year.

Should investors sell immediately? Or is it worth buying BioNTech?

Boardroom turbulence adds another layer of uncertainty. Co-founders Uğur Şahin and Özlem Türeci are stepping down as CEO and chief medical officer, respectively, at year-end. Market watchers say a strong successor could inject fresh momentum, but the transition also opens the door to strategic drift. In a separate move that caught some investors’ attention, Chief Operating Officer Sierk Poetting sold 50,000 shares in April, netting about $5.5 million under a preset trading plan.

The stock has felt the weight of these crosscurrents. BioNTech closed at €79.45 on Friday, down nearly 10% year to date and languishing below its 200-day moving average. Yet when the restructuring news broke on Monday, the shares bounced 2.2% to €81.20, a level that is now testing the 50-day line at €82.74. Chart technicians view a decisive break above that threshold as an early technical vindication of the new strategy.

The next catalyst arrives at the end of May, when BioNTech will present phase 2 data for its non-small cell lung cancer candidate Pumitamab at the ASCO conference. The company is also advancing Pumitamig and recently unveiled phase 2 results for Trastuzumab Pamirtecan in a form of uterine cancer. These readouts will provide the most concrete evidence yet that the oncology pivot can deliver. With several billion euros required to bring a new cancer drug to market, the industry-wide shift toward oncology and immunology among German pharma players makes BioNTech’s high-stakes transformation a closely watched test case.